Genprex to Showcase Innovations in Gene Therapy at BIO International Convention 2026

Genprex, Inc., a clinical-stage gene therapy company based in Austin, Texas, is set to make a significant impact at the upcoming BIO International Convention, scheduled from June 22-25, 2026, in San Diego, California. This prestigious event is widely regarded as the largest gathering of biotechnology professionals globally, attracting over 20,000 industry leaders, researchers, and innovators from around the world.

Focus on Pioneering Therapies

Genprex is dedicated to developing transformative therapies that target serious health conditions, specifically cancer and diabetes. The company's flagship programs feature its cutting-edge gene therapy technologies designed to provide viable treatment options for patients who have previously had limited choices. These innovations showcase Genprex’s commitment to facilitating groundbreaking research and drug development that can ultimately alter the landscape of cancer and diabetes treatment.

Executive Representation

During the convention, Genprex will be represented by key members of its leadership team, including Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. Gallagher will be actively engaging with attendees to discuss the company’s gene therapies and their potential impacts on current treatment protocols. Industry groups interested in exploring potential collaborations or learning more about Genprex's offerings can arrange one-on-one meetings with Gallagher through the conference’s meeting portal or by directly reaching out to the Investor Relations team.

A Snapshot of Genprex's Innovations

Genprex's efforts include the development of the Oncoprex® Delivery System, a sophisticated non-viral method that uses lipid-based nanoparticles to encapsulate gene-expressing plasmids. This delivery mechanism is administered intravenously, targeting tumor cells and encouraging them to express tumor suppressor proteins that are often deficient, providing a novel approach to oncology treatment.

Moreover, the company’s lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently under investigation in two clinical trials aimed at treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both programs have earned Fast Track Designation from the FDA, underscoring the urgency and promise of Genprex's therapeutic developments.

In the realm of diabetes, Genprex is pioneering an infusion technique utilizing an AAV vector to deliver critical genes directly to the pancreas, thus endeavoring to rejuvenate the insulin-producing beta cells. The innovation has demonstrated efficacy in preclinical models for both Type 1 and Type 2 diabetes, potentially transforming how these chronic conditions are managed.

Strong Industry Reception

The BIO International Convention serves as a platform for Genprex to not only showcase their advancements but also to cultivate partnerships and explore new avenues for collaboration. Attendees will have the opportunity to engage with the Genprex team to discuss current research findings, insights into regulatory pathways, and the overall vision for the future of gene therapy.

Genprex encourages those interested in their innovative therapies to stay connected. Investors and stakeholders can receive timely updates and press releases by visiting the Genprex website, where they can also subscribe for email alerts.

Conclusion

The BIO International Convention 2026 promises to be a pivotal event for Genprex as they forge ahead in their mission to bring life-changing therapies to patients in need. As they prepare for the event, Genprex remains focused on their goal of developing new therapeutic options that might one day transform the standard of care in cancer and diabetes treatment. Stay tuned for exciting developments from Genprex as they continue to break new ground in gene therapy.